Cargando…

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension

OBJECTIVE: Endothelin (ET) receptor antagonists (ERAs) have considerable improvements in pulmonary arterial hypertension (PAH) patients’ symptoms. Macitentan, a novel ERA, has more significant positive effects like reduction of morbidity and mortality in PAH patients by 45% and decreases PAH hospita...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nosrati, Marzieh, Shahmirzadi, Nikinaz Ashrafi, Afzali, Monireh, Zaboli, Pardis, Rouhani, Hasti, Hamedifar, Haleh, Hajimiri, Mirhamed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567197/ https://www.ncbi.nlm.nih.gov/pubmed/33102342 http://dx.doi.org/10.4103/jfmpc.jfmpc_1166_19

Ejemplares similares

Iranian Pharmacists’ Knowledge, Attitude and Practice Regarding Counterfeit Drugs
por: Shahverdi, Shieda, et al.
Publicado: (2012)

Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study
por: Corallo, Claudio, et al.
Publicado: (2016)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension
por: Iglarz, Marc, et al.
Publicado: (2015)

Assessment of Influential Variables in the Pricing of Locally Manufactured Pharmaceuticals: Current Challenging Situation in Iran
por: Ashrafi Shahmirzadi, Nikinaz, et al.
Publicado: (2021)

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
por: Li, Jie, et al.
Publicado: (2022)

Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes
por: Lepist, Eve-Irene, et al.
Publicado: (2014)

An educational intervention to improve nurses’ knowledge, attitude, and practice toward reporting of adverse drug reactions
por: Hanafi, Somayeh, et al.
Publicado: (2014)

Bosentan monohydrate
por: Kaur, Manpreet, et al.
Publicado: (2012)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
por: Monaco, Thomas J, et al.
Publicado: (2016)

Studies on the Vitrified and Cryomilled Bosentan
por: Minecka, Aldona, et al.
Publicado: (2021)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

Assessment of Pharmacists Experiences and Attitudes Toward Professionalism and its Challenges in Pharmacy Practice
por: Javadi, Mohammadreza, et al.
Publicado: (2018)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Macitentan in the treatment of pulmonary hypertension in Gaucher’s disease
por: Taylan, Gökay, et al.
Publicado: (2020)

The effect of Bosentan on healing of colonic anastomosis
por: Cetinkaya, Ziya, et al.
Publicado: (2006)

Macitentan: An important addition to the treatment of pulmonary arterial hypertension
por: Khadka, Anjan, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

The use of Macitentan in Fontan circulation: a case report
por: Demetriades, Polyvios, et al.
Publicado: (2017)

Exploring the failing right ventricle in pulmonary hypertension by cardiac magnetic resonance: An in vivo study utilizing Macitentan
por: Murphy, Gerard, et al.
Publicado: (2022)

Review of bosentan in the management of pulmonary arterial hypertension
por: Gabbay, Eli, et al.
Publicado: (2007)

Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan
por: De Haro, Joaquin, et al.
Publicado: (2012)

Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports
por: Ito, Tomoki, et al.
Publicado: (2014)

The relationship between clinical parameters and lifestyle variables among patients with severity of coronary artery stenosis: A cross-sectional analysis based on the severity of coronary artery stenosis
por: Pouya, Hossein Mohseni, et al.
Publicado: (2017)

Swift and Complete Healing of Digital Ulcers after Macitentan Treatment
por: Giner Serret, Emilio
Publicado: (2016)

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension
por: Jung, Hae Ok
Publicado: (2018)

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
por: Wong, Alexandra K, et al.
Publicado: (2019)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

The Endothelin Receptor Antagonist Macitentan Inhibits Human Cytomegalovirus Infection
por: Landázuri, Natalia, et al.
Publicado: (2021)

Effects of bergapten on the pharmacokinetics of macitentan in rats both in vitro and in vivo
por: Xu, Jia, et al.
Publicado: (2023)

Efficacy and safety of macitentan for pulmonary hypertension: A meta‐analysis
por: Du, Dan, et al.
Publicado: (2023)

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
por: Roberts, Kari E, et al.
Publicado: (2009)

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
por: Chinello, Pierangelo, et al.
Publicado: (2011)

Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
por: Onda, Naomi, et al.
Publicado: (2014)

Medical Biotechnology Trends and Achievements in Iran
por: Mahboudi, Fereidoun, et al.
Publicado: (2012)

Macitentan: entry-into-humans study with a new endothelin receptor antagonist
por: Sidharta, Patricia N., et al.
Publicado: (2011)

Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series
por: Mathijssen, H., et al.
Publicado: (2020)

Macitentan attenuates cardiovascular remodelling in infant rats with chronic lung disease
por: Baumann, Philipp, et al.
Publicado: (2022)

Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report
por: Lattanzio, Mariangela, et al.
Publicado: (2022)

Macitentan for the Treatment of Refractory Digital Ulcers in Patients With Connective Tissue Diseases
por: Soto Abánades, Clara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f4ocmbesce8deboh72jqjig22n